Versatope Designs Immunity With Our

Transformational Biotechnology Platform


Our designer extracellular transport vesicles provide cross-strain immunity to infectious disease, including Influenza and targeted RNA therapeutics for cancer.


We have a versatile platform based on molecular engineering of Recombinant Extracellular Transport Vesicles (RET-V's).



The Power of RET-V's


  • Display Multiple Viral Variants on a Single Vesicle 
  • Design More Effective Vaccines
  • Deliver therapeutic RNA directly into cancer cells 
  • Protect Against Emerging Strains
  • Confer Long-Term Immunity
  • Rapid Synthesis, Scale up and Distribution
  • Thermostable

A 3-D View of Versatope's Vaccine Design

Take a voyage inside Versatope's vaccine vesicles and learn how we design multi-strain vaccines using probiotic vesicles and why this gives us a competitive advantage over single strain vaccines. 


Share by: